Stimulation of mammary tumourigenesis and inhibition of uterine adenomyosis by suppressed progesterone effects in SHN mice

H. Nagasawa, M. Aoki, T. Mori, K. Yamamoto, T. Inaba, J. I. Mori

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

It has been shown in mice that progesterone stimulates both mammary tumourigenesis and uterine adenomyosis in intact animals in the presence of normal levels of prolactin and oestrogen. From the view-point of the high dependence of progesterone upon other hormones, the effects of suppressed progesterone action on mammary and uterine lesions were studied in this paper. Subcutaneous implantation of RU 486, an antiprogesterone, enhanced preneoplastic and neoplastic mammary gland growth in SHN virgin mice associated with elevated plasma prolactin levels and continued vaginal oestrous stage. This mammary gland growth stimulated by RU 486 was arrested by additional treatment with progesterone. On the contrary, RU 486 treatment markedly suppressed the development of uterine adenomyosis, which was counteracted only by progesterone supplement for a long period in old mice. The previous and the present findings conclude that progesterone stimulates mammary tumourigenesis by acting synergistically with prolactin and oestrogen when the latter hormones are at normal levels, but it prevents tumourigenesis by acting antagonistically with high levels of prolactin and oestrogen. They further confirmed the importance of progesterone in the development of adenomyosis, while its relationship with prolactin and oestrogen is not understood so well as it is in mammary tumourigenesis.

Original languageEnglish
Pages (from-to)827-832
Number of pages6
JournalAnticancer Research
Volume9
Issue number4
Publication statusPublished - 1989
Externally publishedYes

Fingerprint

Adenomyosis
Progesterone
Breast
Prolactin
Mifepristone
Estrogens
Human Mammary Glands
Hormones
Growth

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Nagasawa, H., Aoki, M., Mori, T., Yamamoto, K., Inaba, T., & Mori, J. I. (1989). Stimulation of mammary tumourigenesis and inhibition of uterine adenomyosis by suppressed progesterone effects in SHN mice. Anticancer Research, 9(4), 827-832.

Stimulation of mammary tumourigenesis and inhibition of uterine adenomyosis by suppressed progesterone effects in SHN mice. / Nagasawa, H.; Aoki, M.; Mori, T.; Yamamoto, K.; Inaba, T.; Mori, J. I.

In: Anticancer Research, Vol. 9, No. 4, 1989, p. 827-832.

Research output: Contribution to journalArticle

Nagasawa, H, Aoki, M, Mori, T, Yamamoto, K, Inaba, T & Mori, JI 1989, 'Stimulation of mammary tumourigenesis and inhibition of uterine adenomyosis by suppressed progesterone effects in SHN mice', Anticancer Research, vol. 9, no. 4, pp. 827-832.
Nagasawa, H. ; Aoki, M. ; Mori, T. ; Yamamoto, K. ; Inaba, T. ; Mori, J. I. / Stimulation of mammary tumourigenesis and inhibition of uterine adenomyosis by suppressed progesterone effects in SHN mice. In: Anticancer Research. 1989 ; Vol. 9, No. 4. pp. 827-832.
@article{c9f666a8f00840469b29f4d26b43ceec,
title = "Stimulation of mammary tumourigenesis and inhibition of uterine adenomyosis by suppressed progesterone effects in SHN mice",
abstract = "It has been shown in mice that progesterone stimulates both mammary tumourigenesis and uterine adenomyosis in intact animals in the presence of normal levels of prolactin and oestrogen. From the view-point of the high dependence of progesterone upon other hormones, the effects of suppressed progesterone action on mammary and uterine lesions were studied in this paper. Subcutaneous implantation of RU 486, an antiprogesterone, enhanced preneoplastic and neoplastic mammary gland growth in SHN virgin mice associated with elevated plasma prolactin levels and continued vaginal oestrous stage. This mammary gland growth stimulated by RU 486 was arrested by additional treatment with progesterone. On the contrary, RU 486 treatment markedly suppressed the development of uterine adenomyosis, which was counteracted only by progesterone supplement for a long period in old mice. The previous and the present findings conclude that progesterone stimulates mammary tumourigenesis by acting synergistically with prolactin and oestrogen when the latter hormones are at normal levels, but it prevents tumourigenesis by acting antagonistically with high levels of prolactin and oestrogen. They further confirmed the importance of progesterone in the development of adenomyosis, while its relationship with prolactin and oestrogen is not understood so well as it is in mammary tumourigenesis.",
author = "H. Nagasawa and M. Aoki and T. Mori and K. Yamamoto and T. Inaba and Mori, {J. I.}",
year = "1989",
language = "English",
volume = "9",
pages = "827--832",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4",

}

TY - JOUR

T1 - Stimulation of mammary tumourigenesis and inhibition of uterine adenomyosis by suppressed progesterone effects in SHN mice

AU - Nagasawa, H.

AU - Aoki, M.

AU - Mori, T.

AU - Yamamoto, K.

AU - Inaba, T.

AU - Mori, J. I.

PY - 1989

Y1 - 1989

N2 - It has been shown in mice that progesterone stimulates both mammary tumourigenesis and uterine adenomyosis in intact animals in the presence of normal levels of prolactin and oestrogen. From the view-point of the high dependence of progesterone upon other hormones, the effects of suppressed progesterone action on mammary and uterine lesions were studied in this paper. Subcutaneous implantation of RU 486, an antiprogesterone, enhanced preneoplastic and neoplastic mammary gland growth in SHN virgin mice associated with elevated plasma prolactin levels and continued vaginal oestrous stage. This mammary gland growth stimulated by RU 486 was arrested by additional treatment with progesterone. On the contrary, RU 486 treatment markedly suppressed the development of uterine adenomyosis, which was counteracted only by progesterone supplement for a long period in old mice. The previous and the present findings conclude that progesterone stimulates mammary tumourigenesis by acting synergistically with prolactin and oestrogen when the latter hormones are at normal levels, but it prevents tumourigenesis by acting antagonistically with high levels of prolactin and oestrogen. They further confirmed the importance of progesterone in the development of adenomyosis, while its relationship with prolactin and oestrogen is not understood so well as it is in mammary tumourigenesis.

AB - It has been shown in mice that progesterone stimulates both mammary tumourigenesis and uterine adenomyosis in intact animals in the presence of normal levels of prolactin and oestrogen. From the view-point of the high dependence of progesterone upon other hormones, the effects of suppressed progesterone action on mammary and uterine lesions were studied in this paper. Subcutaneous implantation of RU 486, an antiprogesterone, enhanced preneoplastic and neoplastic mammary gland growth in SHN virgin mice associated with elevated plasma prolactin levels and continued vaginal oestrous stage. This mammary gland growth stimulated by RU 486 was arrested by additional treatment with progesterone. On the contrary, RU 486 treatment markedly suppressed the development of uterine adenomyosis, which was counteracted only by progesterone supplement for a long period in old mice. The previous and the present findings conclude that progesterone stimulates mammary tumourigenesis by acting synergistically with prolactin and oestrogen when the latter hormones are at normal levels, but it prevents tumourigenesis by acting antagonistically with high levels of prolactin and oestrogen. They further confirmed the importance of progesterone in the development of adenomyosis, while its relationship with prolactin and oestrogen is not understood so well as it is in mammary tumourigenesis.

UR - http://www.scopus.com/inward/record.url?scp=0024433910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024433910&partnerID=8YFLogxK

M3 - Article

C2 - 2817809

AN - SCOPUS:0024433910

VL - 9

SP - 827

EP - 832

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4

ER -